{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:57:33Z","timestamp":1780678653389,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Swedish Cancer Society","award":["23 2846 Pj"],"award-info":[{"award-number":["23 2846 Pj"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Biological insights beyond the cell-of-origin (COO) classification can support clinical management in diffuse large B-cell lymphoma (DLBCL). We investigated if Toll-like receptor 9 (TLR9) expression could serve as a prognostic marker in DLBCL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>\n              <jats:italic>TLR9<\/jats:italic> gene expression was analysed in four publicly available cohorts (<jats:italic>n =\u2009<\/jats:italic>2474), and protein expression was investigated in germinal centre B-cell (GCB) and activated B-cell (ABC) DLBCL cell lines. Next, TLR9 protein expression was analysed in 120 diagnostic samples from R-CHOP-treated patients with relapsed\/refractory disease (poor outcome, <jats:italic>n =\u2009<\/jats:italic>50) or in complete remission (good outcome, <jats:italic>n =\u2009<\/jats:italic>70). Associations were evaluated using logistic regression, estimating odds ratios (OR) and 95% confidence intervals (CI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              <jats:italic>TLR9<\/jats:italic> gene expression was higher in ABC DLBCL compared to GCB DLBCL in external cohorts, and similar results were obtained for protein expression in cell lines. In patient samples, high TLR9 protein expression correlated with non-GCB type (<jats:italic>p =<\/jats:italic>\u20090.003) and poor outcome (<jats:italic>p =<\/jats:italic>\u20090.0016). High TLR9 expression remained associated with poor outcome in multivariable analysis after adjusting for COO and other clinical features (OR\u2009=\u20093.36, 95% CI 1.41\u20138.04). In exploratory analyses, a decrease of cell growth in ABC cell lines following inhibition of TLR9 activity with ODN4084-F was suggested.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We conclude that TLR9 correlates with ABC\/non-GCB phenotype and is a potential predictor of poor prognosis in DLBCL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14359-7","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:00:37Z","timestamp":1748430037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toll-like receptor 9 (TLR9) expression correlates with cell of origin and predicts clinical outcome in diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Sulaf Abd","family":"Own","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Xagoraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Stathopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Pan-Hammarstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Rassidakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"14359_CR1","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1182\/blood-2019-123785","volume":"134","author":"KEE Smedby","year":"2019","unstructured":"Smedby KEE, Ekberg S, Eloranta S, Enblad G, Jerkeman M, Andersson P-O, Harrysson S. Treatment intensity, timing of relapse and outcome of 713 relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) in a population-based setting in Sweden. Blood. 2019;134:4111.","journal-title":"Blood"},{"issue":"5","key":"14359_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"4","key":"14359_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551\u2013568.e514.","journal-title":"Cancer Cell"},{"issue":"3","key":"14359_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41375-023-02120-7","volume":"38","author":"W Ren","year":"2024","unstructured":"Ren W, Wan H, Own SA, Berglund M, Wang X, Yang M, Li X, Liu D, Ye X, Sonnevi K. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis. Leukemia. 2024;38(3):610\u201320.","journal-title":"Leukemia"},{"key":"14359_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ebiom.2017.01.027","volume":"16","author":"PP Xu","year":"2017","unstructured":"Xu PP, Zhong HJ, Huang YH, Gao XD, Zhao X, Shen Y, Cheng S, Huang JY, Chen SJ, Wang L, et al. B-cell function gene mutations in diffuse large B-cell lymphoma: a retrospective cohort study. EBioMedicine. 2017;16:106\u201314.","journal-title":"EBioMedicine"},{"issue":"1","key":"14359_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12026-014-8523-2","volume":"59","author":"CM Buchta","year":"2014","unstructured":"Buchta CM, Bishop GA. Toll-like receptors and B cells: functions and mechanisms. Immunol Res. 2014;59(1):12\u201322.","journal-title":"Immunol Res"},{"issue":"5","key":"14359_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.4049\/jimmunol.1600757","volume":"198","author":"J Pohar","year":"2017","unstructured":"Pohar J, Yamamoto C, Fukui R, Cajnko M-M, Miyake K, Jerala R, Ben\u010dina M. Selectivity of human TLR9 for double CpG motifs and implications for the recognition of genomic DNA. J Immunol. 2017;198(5):2093\u2013104.","journal-title":"J Immunol"},{"issue":"8","key":"14359_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4049\/immunohorizons.1900030","volume":"3","author":"EJ Wigton","year":"2019","unstructured":"Wigton EJ, DeFranco AL, Ansel KM. Antigen complexed with a TLR9 agonist Bolsters c-Myc and mTORC1 activity in germinal center B lymphocytes. ImmunoHorizons. 2019;3(8):389\u2013401.","journal-title":"ImmunoHorizons"},{"issue":"7718","key":"14359_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560(7718):387\u201391.","journal-title":"Nature"},{"issue":"8","key":"14359_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih C-J, Williams PM, Shaffer AL, Gerecitano J, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922\u20136.","journal-title":"Nat Med"},{"issue":"8","key":"14359_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14737140.2021.1915136","volume":"21","author":"Y Jin","year":"2021","unstructured":"Jin Y, Zhuang Y, Dong X, Liu M. Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy. Expert Rev Anticancer Ther. 2021;21(8):841\u201351.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"14359_CR12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/08880018.2019.1667461","volume":"36","author":"R Ronsley","year":"2019","unstructured":"Ronsley R, Kariminia A, Ng B, Mostafavi S, Reid G, Subrt P, Hijiya N, Schultz KR. The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009\u2013008 phase I study. Pediatr Hematol Oncol. 2019;36(8):468\u201381.","journal-title":"Pediatr Hematol Oncol"},{"key":"14359_CR13","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.2147\/OTT.S247050","volume":"13","author":"L Karapetyan","year":"2020","unstructured":"Karapetyan L, Luke JJ, Davar D. Toll-like receptor 9 agonists in cancer. Onco Targets Ther. 2020;13:10039\u201360.","journal-title":"Onco Targets Ther"},{"key":"14359_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fcell.2020.00262","volume":"8","author":"B An","year":"2020","unstructured":"An B, Zhu S, Li T, Wu J, Zang G, Lv X, Qiao Y, Huang J, Shao Y, Cui J, et al. A Dual TLR7\/TLR9 inhibitor HJ901 inhibits ABC-DLBCL expressing the MyD88 L265P mutation. Front Cell Dev Biol. 2020;8:262\u2013262.","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"14359_CR15","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1182\/blood.V124.21.3101.3101","volume":"124","author":"L Brenner","year":"2014","unstructured":"Brenner L, Arbeit RD, Sullivan T. IMO-8400, an Antagonist of Toll-like receptors 7, 8, and 9, in development for genetically defined B-cell lymphomas: safety and activity in phase 1 and phase 2 clinical trials. Blood. 2014;124(21):3101.","journal-title":"Blood"},{"issue":"1","key":"14359_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12967-017-1152-5","volume":"15","author":"L Bai","year":"2017","unstructured":"Bai L, Chen W, Chen J, Li W, Zhou L, Niu C, Han W, Cui J. Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application. J Transl Med. 2017;15(1):51.","journal-title":"J Transl Med"},{"issue":"15","key":"14359_CR17","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"3","key":"14359_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.18.01314","volume":"37","author":"C Sha","year":"2019","unstructured":"Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, Kennedy H, Thompson JS, Uddin R, Worrillow L, et al. Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol. 2019;37(3):202\u201312.","journal-title":"J Clin Oncol"},{"issue":"20","key":"14359_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, Cooke SL, Ruiz C, Glover P, Van Hoppe SJL, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759\u201371.","journal-title":"Blood"},{"issue":"22","key":"14359_CR20","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313\u201323.","journal-title":"N Engl J Med"},{"key":"14359_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2340\/1651-226X.2024.40431","volume":"63","author":"K Ekstr\u00f6m Smedby","year":"2024","unstructured":"Ekstr\u00f6m Smedby K, Eloranta S, W\u00e4sterlid T, Falini V, Jerlstr\u00f6m U, Ellin F, Papworth K, Westerberg J, Lewerin C, Andersson PO, et al. The National Swedish Lymphoma Register - a systematic validation of data quality. Acta oncologica (Stockholm, Sweden). 2024;63:563\u201372.","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"1","key":"14359_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41408-020-00403-1","volume":"11","author":"S Harrysson","year":"2021","unstructured":"Harrysson S, Eloranta S, Ekberg S, Enblad G, Jerkeman M, Wahlin BE, Andersson PO, Smedby KE. Incidence of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9.","journal-title":"Blood Cancer J"},{"issue":"1","key":"14359_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, M\u00fcller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"3","key":"14359_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.17352","volume":"193","author":"I Xagoraris","year":"2021","unstructured":"Xagoraris I, Vassilakopoulos TP, Drakos E, Angelopoulou MK, Panitsas F, Herold N, Medeiros LJ, Giakoumis X, Pangalis GA, Rassidakis GZ. Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. Br J Haematol. 2021;193(3):488\u201396.","journal-title":"Br J Haematol"},{"issue":"4","key":"14359_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","volume":"57","author":"T Kawai","year":"2024","unstructured":"Kawai T, Ikegawa M, Ori D, Akira S. Decoding Toll-like receptors: recent insights and perspectives in innate immunity. Immunity. 2024;57(4):649\u201373.","journal-title":"Immunity"},{"issue":"10","key":"14359_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1182\/blood.2022017534","volume":"140","author":"R Wen","year":"2022","unstructured":"Wen R, Wang D. MCD-DLBCL arises from germinal center B cells. Blood. 2022;140(10):1058\u20139.","journal-title":"Blood"},{"issue":"6","key":"14359_CR27","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2008-02-140673","volume":"112","author":"D Chiron","year":"2008","unstructured":"Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood. 2008;112(6):2205\u201313.","journal-title":"Blood"},{"issue":"11","key":"14359_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1600-0463.2012.02915.x","volume":"120","author":"W-T Huang","year":"2012","unstructured":"Huang W-T, Weng S-W, Huang C-C, Lin H-C, Tsai P-C, Chuang J-H. Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NF\u03baB pathway. APMIS. 2012;120(11):872\u201381.","journal-title":"APMIS"},{"issue":"5","key":"14359_CR29","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3892\/ol.2013.1204","volume":"5","author":"MR V\u00e4is\u00e4nen","year":"2013","unstructured":"V\u00e4is\u00e4nen MR, Jukkola-Vuorinen A, Vuopala KS, Selander KS, Vaarala MH. Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer. Oncol Lett. 2013;5(5):1659\u201363.","journal-title":"Oncol Lett"},{"issue":"1","key":"14359_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/gtmb.2020.0170","volume":"25","author":"A Singh","year":"2020","unstructured":"Singh A, Bandyopadhyay A, Mukherjee N, Basu A. Toll-like receptor 9 expression levels in breast carcinoma correlate with improved overall survival in patients treated with neoadjuvant chemotherapy and could serve as a prognostic marker. Genet Test Mol Biomarkers. 2020;25(1):12\u20139.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"1","key":"14359_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7150\/jca.37033","volume":"11","author":"J Qian","year":"2020","unstructured":"Qian J, Meng H, Lv B, Wang J, Lu Y, Su L, Zhao S, Li W. High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center. J Cancer. 2020;11(1):57.","journal-title":"J Cancer"},{"issue":"10","key":"14359_CR32","first-page":"2207","volume":"6","author":"C Sun","year":"2016","unstructured":"Sun C, Wang G, Wrighton KH, Lin H, Songyang Z, Feng XH, Lin X. Regulation of p27(Kip1) phosphorylation and G1 cell cycle progression by protein phosphatase PPM1G. Am J Cancer Res. 2016;6(10):2207\u201320.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"14359_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.imbio.2016.06.009","volume":"222","author":"M Dajon","year":"2017","unstructured":"Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology. 2017;222(1):89\u2013100.","journal-title":"Immunobiology"},{"issue":"6","key":"14359_CR34","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1158\/1078-0432.CCR-18-1226","volume":"25","author":"M Nie","year":"2019","unstructured":"Nie M, Yang L, Bi X, Wang Y, Sun P, Yang H, Liu P, Li Z, Xia Y, Jiang W. Neutrophil extracellular traps induced by IL8 promote diffuse large B-cell lymphoma progression via the TLR9 signaling. Clin Cancer Res. 2019;25(6):1867\u201379.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"14359_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-16-0786","volume":"77","author":"B Manfroi","year":"2017","unstructured":"Manfroi B, McKee T, Mayol JF, Tabruyn S, Moret S, Villiers C, Righini C, Dyer M, Callanan M, Schneider P, et al. CXCL-8\/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL. Can Res. 2017;77(5):1097\u2013107.","journal-title":"Can Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14359-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14359-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14359-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:00:38Z","timestamp":1748430038000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14359-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14359"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14359-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The regional ethics committee in Stockholm approved the study (Dnr 2015\/2028\u201331\/2).The authors confirmed that all experiments using human tissue samples were performed in accordance with relevant guidelines and regulations. Written informed consent was obtained from living participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"959"}}